PDS Biotechnology Corp (PDSB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $107.07M
Last updated: Nov 17, 2026 at 11:05 AM ET
PDS Biotechnology Corp (PDSB) Competitors
The companies most similar to PDS Biotechnology are PolyPid (PYPD), Pmv Pharmaceuticals (PMVP) and Protara Therapeutics (TARA). By market cap, PDS Biotechnology ranks 9th of the 13 companies on this page; Zentalis Pharmaceuticals Llc (ZNTL) is the largest at $167.05M.
Peer Comparison
PDSB's ROIC of -149.8% is below the peer median of -74.1%, and its revenue growth of 0.0% is in line with the median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| PDS Biotechnology (PDSB) | $107.07M | N/A | N/A | 0.0% | -149.8% | 0.0% | 0.00% |
| PolyPid (PYPD) | $132.25M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Pmv Pharmaceuticals Inc (PMVP) | $95.93M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Protara Therapeutics Inc (TARA) | $155.77M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tiziana Life Sciences Ltd (TLSA) | $72.53M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Cellectis SA (CLLS) | $118.86M | N/A | 1.8x | 0.0% | -74.1% | -85.4% | 0.00% |
| Compass Therapeutics Inc. (CMPX) | $139.35M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Molecular Partners AG ADR (MOLN) | $112.71M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Fate Therapeutics Inc (FATE) | $155.74M | N/A | 29.7x | 0.0% | -51.3% | 9.2% | 0.00% |
| Sutro Biopharma (STRO) | $163.03M | N/A | 3.4x | 0.0% | N/A | -6.1% | 0.00% |
| OUTLOOK THERAPEUTICS INC (OTLK) | $100.54M | N/A | N/A | 0.0% | -776.9% | -99.4% | 0.00% |
| Immunic Inc (IMUX) | $102.61M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Zentalis Pharmaceuticals Llc (ZNTL) | $167.05M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $125.56M | N/A | 3.4x | 0.0% | -74.1% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to PDS Biotechnology, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| PolyPid (PYPD) | PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX)... | PYPD competitors |
| Pmv Pharmaceuticals Inc (PMVP) | PMV Pharmaceuticals, Inc., a precision oncology company, is dedicated to the discovery and development of small molecule tumor agnostic therapies for p53... | PMVP competitors |
| Protara Therapeutics Inc (TARA) | Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment... | TARA competitors |
| Tiziana Life Sciences Ltd (TLSA) | Tiziana Life Sciences Plc, a clinical-stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat... | |
| Cellectis SA (CLLS) | Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors... | CLLS competitors |
| Compass Therapeutics Inc. (CMPX) | Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple... | CMPX competitors |
| Molecular Partners AG ADR (MOLN) | Molecular Partners AG is a clinical-stage biopharmaceutical company. The company is headquartered in Schlieren, Switzerland. | MOLN competitors |
| Fate Therapeutics Inc (FATE) | Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. | FATE competitors |
| Sutro Biopharma (STRO) | Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company. | STRO competitors |
| OUTLOOK THERAPEUTICS INC (OTLK) | Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic... | OTLK competitors |
| Immunic Inc (IMUX) | Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune... | IMUX competitors |
| Zentalis Pharmaceuticals Llc (ZNTL) | Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment... | ZNTL competitors |
Frequently Asked Questions About PDSB
Who are PDS Biotechnology's main competitors?
The companies most similar to PDS Biotechnology include PolyPid (PYPD), Pmv Pharmaceuticals (PMVP), Protara Therapeutics (TARA), Tiziana Life Sciences (TLSA) and Cellectis SA (CLLS), listed from the closest match.
Who is PDS Biotechnology's biggest competitor?
Zentalis Pharmaceuticals Llc (ZNTL) is the largest of the similar companies at $167.05M; PolyPid (PYPD) is the closest match by business profile, size, sector and industry.
How does PDSB stock compare with its competitors?
PDSB's net margin is 0.0% against a peer median of 0.0%.
Which of PDS Biotechnology's competitors pays a higher dividend?
PDS Biotechnology pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is PDS Biotechnology bigger than its competitors?
No. PDS Biotechnology is 9th by market cap among the 13 companies on this page; the largest is Zentalis Pharmaceuticals Llc (ZNTL) at $167.05M.
PDSB pages: Overview, Earnings, Forecast, Financials, Competitors